Sign in Subscribe
Cancer

Rising Incidence of Early-Stage Kidney Cancer Drives Comparative Effectiveness Research

Strategic Insights

— 1 min read

Research published in the journal Clinical Genitourinary Cancer has highlighted the increasing incidence of early-stage kidney cancer, leading to a focus on comparative effectiveness research using cancer registry and administrative data. The study, led by Gianpaolo Carpinito and colleagues from the University of North Carolina Chapel Hill, aimed to better understand the limitations of these data sources for small renal masses (SRM). By analyzing patients diagnosed with clinical T1 renal masses from 2019 to 2020, the researchers identified significant differences in demographic and clinical characteristics across three SRM data sources, including an institutional cancer registry, a prospective clinical trial, and electronic health record (EHR) extraction.

Key Takeaways:

  • The research focused on the rising incidence of early-stage kidney cancer, with a particular emphasis on small renal masses (SRM).
  • The study used cancer registry and administrative data, which may be biased for SRM due to the lack of histologic confirmation prior to treatment.
  • The researchers compared characteristics of patient populations across three SRM data sources: an institutional cancer registry, a prospective clinical trial, and electronic health record (EHR) extraction.
  • Among 555 cases, 169 (30.5%) were in the clinical trial, 273 (49.2%) in the cancer registry only, and 113 (20.4%) from EHR extraction only.
  • Active surveillance was more common in the EHR extraction cohort (85%) than in the registry (48%) or trial (33%) (P<0.001).
  • The study concluded that standardized radiologic reporting and revised registry criteria may ensure more complete data for early-stage kidney cancer.

Statistics:

  • 555 cases of clinical T1 renal masses were analyzed from 2019 to 2020.
  • 169 (30.5%) cases were in the clinical trial, 273 (49.2%) in the cancer registry only, and 113 (20.4%) from EHR extraction only.
  • Active surveillance was reported in 85% of the EHR extraction cohort, 48% of the registry cohort, and 33% of the trial cohort.
  • The differences in demographic and clinical characteristics across cohorts were statistically significant (P<0.001).

Sources:

  • Carpinito, G., et al. (2025). Data Sources for Clinical T1 Renal Masses and the Potential for Bias. Clinical Genitourinary Cancer, 23(6), 102435.
  • Clinical Genitourinary Cancer. (2025). Volume 23, Issue 6. Elsevier.

Read more